MINNEAPOLIS (February 20, 2018) – OneOme, a healthcare technology company whose genetic test helps predict how a person will respond to hundreds of medications and enables healthcare providers to prescribe more effective medications, today announced that it is included in Fast Company’s annual ranking of the 50 Most Innovative Companies for 2018. OneOme, which is co-developed and exclusively licensed from Mayo Clinic, earned the No. 22 spot in the overall ranking and the second spot on the Top 10 Most Innovative Companies in Biotech list. The Top 50 list also includes Apple (No. 1), Netflix, Amazon, NBA, and Spotify.
Fast Company’s annual list, which the publication says includes companies that “have embraced innovation and are working to make meaningful change,” honors leading enterprises and rising newcomers that exemplify the best in business and innovation. Fast Company recognized OneOme for its RightMed® comprehensive test, a pharmacogenomic test (sometimes called a medication response test) that helps to identify which medications may — or may not — work best for a patient.
“Before advancements in precision medicine and genetics, providers had to rely on trial and error to find the right medication for their patients,” said Paul Owen, chief executive officer at OneOme. “Now with OneOme’s RightMed solution, we can predict how someone is likely to respond to a medication before they take it, which may help reduce adverse drug reactions and medication side effects, increase medication effectiveness, and alleviate prescription drug expenditures.”
OneOme’s RightMed comprehensive test analyzes a person’s DNA to predict how they will respond to more than 340 medications used to treat more than 30 medical conditions, including anxiety, depression, pain, nausea, cancer, and more. The RightMed test must be ordered by a provider. Patients can either talk to their doctor about the test using tips from OneOme’s patient toolkit or can request a test on OneOme’s website (eligibility restrictions may apply).
OneOme was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit oneome.com.
About Fast Company
Fast Company is the world’s leading progressive business media brand, with a unique editorial focus on innovation in technology, ethical economics, leadership, and design. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, one of the U.S.’s leading media companies.
Editor’s Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.